650 Chapel Street
Suite 0403 Level 4
South Yarra, VIC 3141
Australia
61 3 9826 0399
https://opthea.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 24
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. | Founder, Chief Innovation Officer & Executive Director | 599,73k | S.O. | 1975 |
Dr. Frederic Guerard M.S., Pharm.D. | Chief Executive Officer | S.O. | S.O. | 1973 |
Ms. Sarika Gulhar Ph.D. | Executive Director of Human Resources | S.O. | S.O. | S.O. |
Dr. Michael Gerometta Ph.D. | Head of Chemistry, Manufacturing & Controls Development | 132,49k | S.O. | 1965 |
Mr. Bruno Gagnon BPHARM, M.Sc. | Senior Vice President of Global Clinical Operations | S.O. | S.O. | 1969 |
Dr. Kenneth Sall | Chief Medical Officer | S.O. | S.O. | S.O. |
Dr. Fang Li Ph.D. | Senior Vice President of Regulatory Affairs | S.O. | S.O. | S.O. |
Dr. Julie Clark M.D., M.S. | Senior Vice President of Clinical Development | S.O. | S.O. | S.O. |
Dr. Arshad M. Khanani M.A., M.D. | Chief Medical Advisor | S.O. | S.O. | S.O. |
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
L’ISS Governance QualityScore de Opthea Limited en date du 1 mai 2024 est 9. Les scores principaux sont Audit : 10; Société : 6; Droits des actionnaires : 10; Compensation : 10.